Annual Report
To maximize corporate value, the Noevir Group follows a management strategy that responds flexibly and rapidly to changes in the operating environment.
Hiroshi Okura, Chairman and Representative Director
Takashi Okura, President and Representative Director

  Results for First-Half of Fiscal 2010(Sept. 21, 2009 -Sept. 20, 2010)

Though increased exports and other improvements could be seen in some areas of the Japanese economy during the reporting six-month period (September 21, 2009 - March 20, 2010), the challenging employment situation continued and individual consumer spending remained sluggish.
In the cosmetics market, which forms the core of the Noevir Group´s business, adverse conditions continued as consumers orient toward low prices.
For cosmetics sold through individual consultation, amid this difficult operating environment, we worked to develop high added-value products and to raise the image of our brand as a high-end cosmetics line through our sales representatives.
For our cosmetics products and energy drinks sold primarily through drug stores, and for our functional drinks retailed mainly through convenience stores, we implemented aggressive advertising and sales promotion campaigns.
As a result, for the reporting first-half period, the Noevir Group recorded sales on a consolidated basis of 26,765 million yen, a year-on-year decrease of 6.5%. Operating income was 2,134 million yen, down 12.7% from the same period in the previous year. Ordinary income declined 14.8% year-on-year to 2,280 million yen, while net income came in at 1,121 million yen, a drop of 1.1%.

  Future Prospects

Despite the harsh business environment in which the Group is now operating, in cosmetics products sold through individual consultation, we plan to launch items more closely tailored to customer needs, and to strengthen partnerships with sales representatives.
In self-selection cosmetics, we will continue to launch highly talked-about products, and expand market share through aggressive advertising and promotional activities. We will also raise our profile in the Asian market through our exhibit at the Japan Industry Pavilion at Expo 2010 Shanghai, and other measures.
In the pharmaceutical segment, the goal is to make our brands popular among a wide range of age groups by improving name recognition of major brands and developing the products that best meet market needs.
In the health food segment, we will further strengthen our market position by promotional activities geared to new target groups for functional drinks.
We will continue to take a cautious stance in the "Other" segment, despite signs of a pickup in the aviation business on the back of global economic recovery.
We would like to thank all the Company´s shareholders on behalf of the management and employees of Noevir, and we look forward to your continued support and encouragement.